One of the top 50 start ups in french-speaking Switzerland

Geneva, Switzerland, December 18, 2019.


Abologix has received recognition in “Bilan” as one of the most promising swiss start-ups in the french speaking cantons of Switzerland. The company has been invited to address a group of potential investors in a future meeting to be held in Lausanne, Switzerland.


About Abologix Abologix is a pre-clinical stage biopharmaceutical companydeveloping best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3)for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Genevaand the Hôpitaux Universitaires de Genève.

ABOLOGIX awarded a two year Innosuisse Innovation

Geneva, Switzerland, Juy 24, 2020. Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner

Copyright © 2021 ABOLOGIX